版本:
中国

BRIEF-Agilent Technologies, Agendia to develop RNA-SEQ kit version of Agendia's mammaprint, blueprint tests

June 2 Agilent Technologies Inc:

* Co, Agendia Inc to expand relationship to develop RNA-SEQ kit version of Agendia's currently marketed mammaprint, blueprint tests

* Agreement accelerates development of tests to assess risk of disease recurrence in women with early-stage breast cancer

* Initial phase of RNA-SEQ kit development is expected to be completed in 2017, providing early access to limited markets in Europe Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐